Holen Sie sich die Stockscreener-App
6.23
2.20%
-0.14
Handel nachbörslich:
6.04
-0.19
-3.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.37
Offen:
$6.32
24-Stunden-Volumen:
2.16M
Relative Volume:
1.22
Marktkapitalisierung:
$482.92M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-2.0493
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+15.58%
1M Leistung:
+30.06%
6M Leistung:
+99.68%
1J Leistung:
-28.64%
1-Tages-Spanne:
$5.74
$6.35
1-Wochen-Bereich:
$5.40
$6.95
52-Wochen-Spanne:
$2.41
$10.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.23 | 417.81M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
What drives Solid Biosciences Inc. stock priceFree Trading Psychology Coaching - Autocar Professional
Is Solid Biosciences Inc. a good long term investmentExponentially increasing returns - jammulinksnews.com
Solid Biosciences Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Cantor Fitzgerald Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
What analysts say about Solid Biosciences Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Solid Biosciences stock rating reiterated at Market Outperform by JMP - Investing.com Canada
What institutions are buying Solid Biosciences Inc. stock nowSteady Income Ideas - beatles.ru
Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com Nigeria
Citi maintains Buy rating on Solid Biosciences stock amid Elevidys safety concerns - Investing.com Canada
Why Solid Biosciences Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
What makes Solid Biosciences Inc. stock price move sharplyFree Investment Group - beatles.ru
Cantor Fitzgerald Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade) - Seeking Alpha
Truist Financial Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm - The Victoria Advocate
For Patients - Solid Biosciences
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - MSN
Solid Biosciences: A Rare Gem in the Gene Therapy Race - AInvest
Solid Biosciences Inc. Initiated with 'Buy' Rating and $14 PT by Citi - AInvest
Solid Biosciences to begin testing SGT-501 in U.S. and Canada (SLDB) - Seeking Alpha
Solid Biosciences cleared to begin phase I studies of SGT-501 in US and Canada - BioWorld MedTech
Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes - Stocktwits
Solid Biosciences receives FDA approval for CPVT gene therapy IND By Investing.com - Investing.com South Africa
Solid Biosciences receives FDA approval for CPVT gene therapy IND - Investing.com Australia
Solid Biosciences gets FDA IND, Health Canada CTA nod for first-in-class cardiac gene therapy CPVT - MarketScreener
Solid Biosciences Gets FDA, Health Canada Clearance to Advance Gene Therapy Trial for Cardiac Disease - MarketScreener
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - The Manila Times
Breakthrough: First Gene Therapy for Fatal Heart Rhythm Disorder Advances to Clinical Trials - Stock Titan
Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid challenges By Investing.com - Investing.com South Africa
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Solid Biosciences Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018SLDB - ACCESS Newswire
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):